- Mast Therapeutics (MSTX) is up 12% in early action.
- The company says MST-188 "demonstrated a statistically significant improvement in numerous parameters of heart function," in a nonclinical heart failure model.
- The data collected suggest the treatment may be promising way to improve left ventricular ejection fraction and end-systolic volume.
- The company intends to "provide an update on its plans for MST-188 in heart failure later in 2014." (PR)
Mast Therapeutics rallies on heart failure data
Jan 6 2014, 08:51 ET